September 01, 2016
1 min read
Save

Young individuals with inflammatory arthritis value treatments that lead to a normal life

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Recently published results showed that although young individuals with inflammatory arthritis place value on treatment that helps them live a normal life, there are profound and lasting emotional, social and vocational consequences of treatment.

Researchers used interviews with 25 young individuals with inflammatory arthritis, as well as audio recordings of patient consultations and focus groups to explore decision-making about biologic therapies. Eleven trusted others and six health professionals took part in the interviews.

Ruth Hart

Results showed treatment of inflammatory arthritis presented both as an opportunity for and a threat to achieving what young people perceived as a normal life, with treatment changes subject to complex and ongoing evaluation. The young people in the study voiced concerns about treatment administration, restrictions associated with treatment, anticipated effects and side effects.

Researchers found the information sources for young individuals on inflammatory arthritis included expert opinion of professionals and other individuals with this condition, as well as personal experience. Important reference points were provided by previous treatments and it was shown young individuals made provisional decisions when faced with uncertain outcomes, according to results. Researchers noted a concern that young individuals were too focused on short-term outcomes was expressed by both the trusted others and health care professionals who participated in the study. – by Casey Tingle

Disclosures: Hart reports no relevant financial disclosures. Please see the full study for a list of all other authors’ relevant financial disclosures.